Myriad Genetics, Inc. has entered into a definitive asset purchase agreement to sell its prenatal health business to Laboratory Corporation of America for $210 million in cash, plus the value of inventory at closing. The divestiture includes several of Myriad's key prenatal screening tests, such as Foresight, Prequel, and the SneakPeek Early Gender Test.
Key Details
- Transaction Terms: The deal, dated October 19, 2026, is valued at $210 million in cash, plus an additional amount for the business's inventory at the time of closing.
- Assets Sold: The sale comprises assets and liabilities of Myriad's prenatal health business, including its Foresight Carrier Screen, Prequel Prenatal Screen, FirstGene 4-in-1 Prenatal Screen, and SneakPeek Early Gender Test.
- Conditions & Timeline: The transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act. The agreement may be terminated if closing does not occur by February 19, 2027, with a potential extension to October 19, 2027, for regulatory clearance.
- Termination Fee: The buyer, Laboratory Corporation of America, may be required to pay Myriad a termination fee of $10.5 million if the agreement is terminated due to a failure to obtain certain regulatory clearances.